drugset / Trial / NCT06169982

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

NCT06169982

Phase 1 Completed 56 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

Timeline

Start
2023-12-07
Primary completion
2024-07-18
Completion
2024-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Efsitora Alfa Protein / enzyme biologic Subcutaneous